Cardiff Oncology, Inc., a biotechnology company operating within the Health Care sector, has recently made significant strides in its strategic partnership with Nerviano Medical Sciences. This development marks a pivotal moment for Cardiff Oncology, Inc., a company dedicated to pioneering therapies and treatments for solid tumor and hematologic cancers. Based in San Diego, United States, Cardiff Oncology, Inc. has been at the forefront of innovation, aiming to provide groundbreaking solutions to combat various types of cancer, primarily serving customers in California.
On September 14, 2026, Cardiff Oncology, Inc. announced a landmark settlement and amendment to its 2017 exclusive license agreement with Nerviano Medical Sciences. This agreement resolves all outstanding litigation concerning the global rights to Cardiff’s lead drug candidate, onvansertib. The settlement not only clears the path for future collaboration but also introduces a new framework for the joint development and commercialization of onvansertib.
The amended agreement is comprehensive, expanding the royalty structure and introducing additional license fees that are directly tied to product sales leveraging Cardiff-patented claims. This financial restructuring is designed to incentivize both parties to maximize the commercial potential of onvansertib. Furthermore, the agreement establishes new milestones and payment terms linked to the Phase III clinical program, ensuring that both Cardiff Oncology, Inc. and Nerviano Medical Sciences are aligned in their objectives and timelines.
In a move that underscores the collaborative spirit of the amended agreement, Nerviano Medical Sciences has been granted a board observer seat and a position on Cardiff’s scientific advisory board. This inclusion allows for a more integrated approach to the development and commercialization of onvansertib, while Cardiff Oncology, Inc. retains ultimate decision-making authority. This balance of power ensures that Cardiff’s strategic vision remains at the forefront of the partnership.
The parties have reaffirmed their commitment to advancing onvansertib toward regulatory approval, with a particular focus on its application in first-line RAS-mutated metastatic colorectal cancer. This focus is critical, as RAS mutations are prevalent in a significant portion of colorectal cancer cases, and effective treatments are in high demand. The amended agreement outlines governance and intellectual-property provisions designed to support continued collaboration, ensuring that both companies can navigate the complex regulatory landscape together.
Cardiff Oncology, Inc.’s market performance, as reflected in its close price of $1.35 on September 15, 2026, and its market capitalization of approximately $105 million, underscores the challenges and opportunities facing the company. Despite a price-earnings ratio of -2.27, indicative of the company’s current financial performance and the speculative nature of its investments, the settlement with Nerviano Medical Sciences represents a significant step forward. It not only resolves past disputes but also sets a clear path for the future development and commercialization of onvansertib.
As Cardiff Oncology, Inc. continues to navigate the complexities of the biotechnology sector, its partnership with Nerviano Medical Sciences stands as a testament to the power of collaboration in the pursuit of innovative cancer treatments. With a renewed focus on onvansertib and a strategic framework in place, Cardiff Oncology, Inc. is well-positioned to make significant contributions to the fight against cancer, particularly in the realm of solid tumor and hematologic cancers. The company’s commitment to serving its customers in California and beyond remains unwavering, as it continues to push the boundaries of what is possible in cancer therapy.
